Literature DB >> 9738975

Significant correlation of nitric oxide synthase activity and p53 gene mutation in stage I lung adenocarcinoma.

H Fujimoto1, J Sasaki, M Matsumoto, M Suga, Y Ando, R Iggo, M Tada, H Saya, M Ando.   

Abstract

Nitric oxide (NO) and its derivatives can directly cause DNA damage and mutation in vitro and may play a role in the multistage carcinogenic process. It has been reported that NO induces mutation in the p53 tumor suppressor gene; we therefore analyzed the relationship between NO synthase (NOS) activity and p53 gene status in early-stage lung adenocarcinoma. Surgical samples were classified into two categories: 14 lung adenocarcinomas with high NOS activity (>25 pmol/min/g tissue, category A), and 16 with low NOS activity (<25 pmol/min/g tissue, category B). A yeast functional assay for p53 mutations disclosed a red colony that corresponded to a mutation in the p53 gene in 8 cases (57.1%) in category A and 3 cases (18.8%) in category B, the frequency being significantly higher in the former (P<0.05). A p53 DNA sequence analysis revealed that 5 of the 8 p53 mutation-positive samples in category A had a G:C-to-T:A transversion, which is reported to be a major target of NO. The mechanism of carcinogenesis of adenocarcinoma is not fully understood, but these results suggest that an excess of endogenously formed NO may induce a p53 gene mutation containing mainly G:C-to-T:A transversion in the early stage of lung adenocarcinoma. Our results suggest that NO has potential mutagenic and carcinogenic activity, and may play important roles in human lung adenocarcinoma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9738975      PMCID: PMC5921893          DOI: 10.1111/j.1349-7006.1998.tb03273.x

Source DB:  PubMed          Journal:  Jpn J Cancer Res        ISSN: 0910-5050


  31 in total

Review 1.  Nitric oxide synthases: roles, tolls, and controls.

Authors:  C Nathan; Q W Xie
Journal:  Cell       Date:  1994-09-23       Impact factor: 41.582

2.  Purification and cDNA sequence of an inducible nitric oxide synthase from a human tumor cell line.

Authors:  P A Sherman; V E Laubach; B R Reep; E R Wood
Journal:  Biochemistry       Date:  1993-11-02       Impact factor: 3.162

3.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

4.  Nitric oxide synthase activity in human gynecological cancer.

Authors:  L L Thomsen; F G Lawton; R G Knowles; J E Beesley; V Riveros-Moreno; S Moncada
Journal:  Cancer Res       Date:  1994-03-01       Impact factor: 12.701

5.  Preferential formation of benzo[a]pyrene adducts at lung cancer mutational hotspots in P53.

Authors:  M F Denissenko; A Pao; M Tang; G P Pfeifer
Journal:  Science       Date:  1996-10-18       Impact factor: 47.728

6.  Difference of allelotype between squamous cell carcinoma and adenocarcinoma of the lung.

Authors:  S Sato; Y Nakamura; E Tsuchiya
Journal:  Cancer Res       Date:  1994-11-01       Impact factor: 12.701

7.  DNA deaminating ability and genotoxicity of nitric oxide and its progenitors.

Authors:  D A Wink; K S Kasprzak; C M Maragos; R K Elespuru; M Misra; T M Dunams; T A Cebula; W H Koch; A W Andrews; J S Allen
Journal:  Science       Date:  1991-11-15       Impact factor: 47.728

8.  A simple p53 functional assay for screening cell lines, blood, and tumors.

Authors:  J M Flaman; T Frebourg; V Moreau; F Charbonnier; C Martin; P Chappuis; A P Sappino; I M Limacher; L Bron; J Benhattar
Journal:  Proc Natl Acad Sci U S A       Date:  1995-04-25       Impact factor: 11.205

Review 9.  Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis.

Authors:  M S Greenblatt; W P Bennett; M Hollstein; C C Harris
Journal:  Cancer Res       Date:  1994-09-15       Impact factor: 12.701

10.  Nitric oxide synthase activity in human breast cancer.

Authors:  L L Thomsen; D W Miles; L Happerfield; L G Bobrow; R G Knowles; S Moncada
Journal:  Br J Cancer       Date:  1995-07       Impact factor: 7.640

View more
  7 in total

1.  Long-term adaptation of breast tumor cell lines to high concentrations of nitric oxide.

Authors:  Benjamin J Vesper; Kim M Elseth; Gabor Tarjan; G Kenneth Haines; James A Radosevich
Journal:  Tumour Biol       Date:  2010-05-18

2.  Plasma bcl-2 and nitric oxide: possible prognostic role in patients with metastatic breast cancer.

Authors:  H E Gaballah; I Abdel Salam; N Abdel Wahab; O M Mansour
Journal:  Med Oncol       Date:  2001       Impact factor: 3.064

3.  Stromal nitric oxide synthase (NOS) expression correlates with the grade of mammary phyllodes tumour.

Authors:  G M K Tse; F C Wong; A K H Tsang; C S Lee; P C W Lui; A W I Lo; B K B Law; R A Scolyer; R Z Karim; T C Putti
Journal:  J Clin Pathol       Date:  2005-06       Impact factor: 3.411

4.  Nitric oxide and inducible nitric oxide synthase levels in EE and NERD patients.

Authors:  Fatemeh Nejat PishKenari; Durdi Qujeq; Seyed Saeid Mohammady Bonahi; Mehrdad Kashifard; Karimollah Hajian-Tilaki
Journal:  Gastroenterol Hepatol Bed Bench       Date:  2022

5.  Part I-mechanism of adaptation: high nitric oxide adapted A549 cells show enhanced DNA damage response and activation of antiapoptotic pathways.

Authors:  Madeeha Aqil; Kim M Elseth; Benjamin J Vesper; Zane Deliu; Bulent Aydogan; Jiaping Xue; James A Radosevich
Journal:  Tumour Biol       Date:  2013-11-16

6.  Association of endothelial nitric oxide synthase (eNOS) polymorphisms with EGFR-mutated lung adenocarcinoma in Taiwan.

Authors:  Chun-Yao Huang; Ming-Ju Hsieh; Wen-Jun Wu; Whei-Ling Chiang; Tu-Chen Liu; Shun-Fa Yang; Thomas Chang-Yao Tsao
Journal:  J Cancer       Date:  2018-06-15       Impact factor: 4.207

Review 7.  Nitric Oxide System and Bronchial Epithelium: More Than a Barrier.

Authors:  María Amparo Bayarri; Javier Milara; Cristina Estornut; Julio Cortijo
Journal:  Front Physiol       Date:  2021-06-30       Impact factor: 4.566

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.